Merck & Co., Inc. Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Merck & Co., Inc. saw a increase in short interest in March. As of March 31st, there was short interest totaling 23,740,000 shares, an increase of 30.9% from the March 15th total of 18,140,000 shares. Based on an average daily volume of 11,960,000 shares, the short-interest ratio is presently 2.0 days. Approximately 0.9% of the shares of the company are sold short.
View Merck & Co., Inc.'s Short Interest.

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Wednesday, February, 3rd. The company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.38 by $0.06. The company had revenue of $12.51 billion for the quarter, compared to analysts' expectations of $12.65 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 53.83% and a net margin of 24.33%. Merck & Co., Inc.'s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.16 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have decreased by 3.7% and is now trading at $76.28.
View which stocks have been most impacted by COVID-19.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, January 27th. Stockholders of record on Monday, March 15th will be paid a dividend of $0.65 per share on Wednesday, April 7th. This represents a $2.60 annualized dividend and a yield of 3.41%. The ex-dividend date of this dividend is Friday, March 12th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.41%. Merck & Co., Inc. does not yet have a strock track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 50.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 42.83% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. updated its FY21 earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of $6-48-6.68 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.19. The company issued revenue guidance of $51.8-53.8 billion, compared to the consensus revenue estimate of $51.58 billion.

14 brokerages have issued 1-year price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $95.92 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of MRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional investors include Royal London Asset Management Ltd. (0.04%), State of Alaska Department of Revenue (0.03%), Cacti Asset Management LLC (0.03%), Calamos Advisors LLC (0.03%), Gofen & Glossberg LLC IL (0.02%) and Neville Rodie & Shaw Inc. (0.01%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including FDx Advisors Inc., Renaissance Investment Group LLC, Park National Corp OH, State of Alaska Department of Revenue, Hexavest Inc., Monument Capital Management, Abner Herrman & Brock LLC, and Hohimer Wealth Management LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, Sanat Chattopadhyay, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

MRK stock was purchased by a variety of institutional investors in the last quarter, including M&R Capital Management Inc., Everence Capital Management Inc., Founders Capital Management LLC, Carolina Wealth Advisors LLC, Curbstone Financial Management Corp, Bonness Enterprises Inc., Calamos Advisors LLC, and Edge Wealth Management LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRK stock can currently be purchased for approximately $76.28.

Merck & Co., Inc. has a market capitalization of $193.02 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis.

Merck & Co., Inc. employs 73,000 workers across the globe.

Merck & Co., Inc. was founded in 1891.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]